Ravi V, Murashima-Suginami A, Kiso H, Tokita Y, Huang C L, Bessho K, Takagi J, Sugai M, Tabata Y, Takahashi K
Toregem BioPharma Inc., Kyoto, Japan.
Department of Oral and Maxillofacial Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
Regen Ther. 2023 Feb 3;22:160-168. doi: 10.1016/j.reth.2023.01.004. eCollection 2023 Mar.
The lack of treatment options for congenital (0.1%) and partial (10%) tooth anomalies highlights the need to develop innovative strategies. Over two decades of dedicated research have led to breakthroughs in the treatment of congenital and acquired tooth loss. We revealed that by inactivating , congenital tooth agenesis can be successfully ameliorated during early tooth development and that the inactivation promotes late-stage tooth morphogenesis in double knockout mice. Furthermore, Anti- antibody treatment in mice is effective in tooth regeneration and can be a breakthrough in treating tooth anomalies in humans. With approximately 0.1% of the population suffering from congenital tooth agenesis and 10% of children worldwide suffering from partial tooth loss, early diagnosis will improve outcomes and the quality of life of patients. Understanding the role of pathogenic variants, their interacting gene partners, and their protein functions will help develop critical biomarkers. Advances in next-generation sequencing, mass spectrometry, and imaging technologies will assist in developing companion and predictive biomarkers to help identify patients who will benefit from tooth regeneration.
先天性（0.1%）和部分性（10%）牙齿异常缺乏治疗选择，这凸显了开发创新策略的必要性。二十多年的专注研究已在先天性和后天性牙齿缺失的治疗方面取得突破。我们发现，通过使 失活，先天性牙齿发育不全在牙齿早期发育过程中可成功改善，且这种失活促进双敲除小鼠的晚期牙齿形态发生。此外，小鼠中的抗 抗体治疗在牙齿再生方面有效，可能成为治疗人类牙齿异常的一项突破。全球约0.1%的人口患有先天性牙齿发育不全，10%的儿童患有部分牙齿缺失，早期诊断将改善患者的治疗效果和生活质量。了解致病 变体、其相互作用的基因伙伴及其蛋白质功能将有助于开发关键的生物标志物。下一代测序、质谱和成像技术的进展将有助于开发伴随和预测性生物标志物，以帮助识别将从牙齿再生中受益的患者。
